Market Overview:

The global histology and cytology market reached a value of US$ 13.22 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 25.72 Billion by 2027, exhibiting a CAGR of 11.20% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Histology and cytology are branches of biology dealing with chemistry, structure and function of tissues and cells of animals and plants at a microscopic level. They assist medical staff in diagnosing diseases, such as cancer, cervical disease, tuberculosis, human papilloma virus (HPV) infection, abnormal growth, inflammatory diseases, leukemia, smallpox, and rabies. They also help enhance the sensitivity, specificity and accuracy of diagnostic methods. As a result, they find extensive applications in hospitals, clinics, and research and development (R&D) institutes across the globe.

Histology and Cytology Market Trends:

At present, there is a rise in the number of cancer patients across the globe. This, along with the favorable reimbursement policies for laboratory tests, represents one of the key factors driving the market. Moreover, the growing integration of digital solutions in cytological diagnosis aids in rapidly interpreting primary diagnostic data, which is positively influencing the market. In addition, major manufacturers are launching new and advanced cytology systems for helping in the rapid on-site evaluation of cytology samples. This, coupled with the rising traction of immunohistochemistry (IHC) for visualizing cellular components, is propelling the growth of the market. Besides this, there is an increase in the standardization of pathological laboratories around the world. This, along with technological advancements in diagnostic and molecular techniques, is contributing to the growth of the market. Additionally, increasing awareness about the advanced therapeutics and enhanced healthcare infrastructure worldwide is offering lucrative growth opportunities to industry investors. Furthermore, key market players are focusing on acquisitions, mergers, partnerships, and collaborations to expand their customer base. They are also launching new products and receiving product approvals from regulatory authorities, which is projected to bolster the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global histology and cytology market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, type of examination, test type and application.

Breakup by Product:

• Instruments and Analysis Software System
• Consumable and Reagents
   

Breakup by Type of Examination:

• Histology
• Cytology
   

Breakup by Test Type:

• Microscopy Tests
• Molecular Genetics Tests
• Flow Cytometry
   

Breakup by Application:

• Drug Discovery and Designing
• Clinical Diagnostics
  • Point-of-Care (PoC)
  • Non-Point-of-Care
• Research
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, Carl Zeiss AG, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., Koninklijke Philips N.V., Merck KGaA, Olympus Corporation, PerkinElmer Inc., Sysmex Corporation, Thermo Fisher Scientific Inc. and Trivitron Healthcare.

Report Coverage: